ChinaMart

China Biotech Week in Review: Earnings, Deals and Drug Development

LTUS (Lotus Pharmaceuticals) reaffirmed 2008 guidance on Friday. That guidance of $13.8M USD in net income is about .29/share fully diluted...making the PE for LTUS well under 4.
As far as I can tell, this makes LTUS the best value in the China Biopharma sector today.

China Pharma Delivers on Improved Financials Promise

The bottom line on ARs in these Chinese pharma micros is how it affects DSO (Days Sales Outstanding). In the case of CPHI, they're increasing and are now at an average of 191 days compared to 184 days last Q).
And, (although this will sound to some like spam), LTUS.OB (Lotus Pharma)for comparison has a much more favorable DSO average of about 90. This tells me that LTUS is converting their ARs into cash at a faster rate, and more successfully than CPHI.

China Pharma Holdings: An Opportunity To Buy A Beloved Stock

I think LTUS.OB (Lotus Pharmaceutical) is another undervalued Chinese pharma stock with similar growth rate. On track to make .18/share for 2007 and trading at about $1/share.

PE for LTUS.OB is about 5 here!